세계의 희소 바이오마커 검체 수집과 안정화 시장

Global Rare Biomarkers Specimen Collection and Stabilization Market to Reach US$87.8 Billion by 2030

The global market for Rare Biomarkers Specimen Collection and Stabilization estimated at US$47.4 Billion in the year 2023, is expected to reach US$87.8 Billion by 2030, growing at a CAGR of 9.2% over the analysis period 2023-2030. Circulating Cell Free DNA (ccfDNA), one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$34.0 Billion by the end of the analysis period. Growth in the Circulating Tumor Cells (CTCs) segment is estimated at 9.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$13.1 Billion While China is Forecast to Grow at 8.5% CAGR

The Rare Biomarkers Specimen Collection and Stabilization market in the U.S. is estimated at US$13.1 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$13.3 Billion by the year 2030 trailing a CAGR of 8.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.4% and 7.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.6% CAGR.

Rare Biomarkers Specimen Collection and Stabilization: Advancing Precision in Biomedical Research

What Are Rare Biomarkers, and Why Is Specimen Collection and Stabilization Important?

Rare biomarkers are specific biological molecules found in limited concentrations in the body, often present in blood, urine, or tissue samples, that indicate a particular disease state, response to treatment, or genetic profile. These biomarkers are essential in the diagnosis, monitoring, and prognosis of various conditions, including cancer, genetic disorders, and neurodegenerative diseases. Detecting rare biomarkers can enable early disease detection, targeted therapies, and personalized medicine approaches. However, their low abundance makes them challenging to identify and measure, especially as they may degrade or change rapidly after specimen collection. Thus, proper specimen collection and stabilization are critical to preserving the integrity and reliability of these biomarkers for accurate analysis.

Effective collection and stabilization of rare biomarkers ensure that they remain unchanged from the moment they are sampled until they are analyzed. This process involves carefully selecting collection devices, using stabilizing agents, and following stringent protocols to prevent biomarker degradation. Improper handling can lead to inaccurate test results, misinterpretation of a disease state, or missed diagnosis, underscoring the importance of stability in precision medicine and research. The growing emphasis on personalized medicine, where rare biomarkers often play a pivotal role, has made collection and stabilization practices a focal point for improving diagnostic accuracy and enabling advanced biomarker research.

What Methods Are Used for Specimen Collection and Stabilization of Rare Biomarkers?

Collecting and stabilizing specimens containing rare biomarkers requires specialized techniques to preserve their structure and functionality. Blood-based biomarkers are frequently collected in specialized tubes containing anticoagulants and stabilizing agents, such as EDTA or heparin, which prevent coagulation and preserve cell-free DNA, RNA, and proteins. For example, for rare biomarkers like circulating tumor DNA (ctDNA), blood collection tubes with proprietary stabilization agents help prevent cellular degradation and maintain nucleic acid integrity for several days, allowing for more accurate downstream analysis. Plasma and serum separation are also essential steps in the stabilization process, as these fluids contain critical biomarker information once separated from whole blood.

For urine and saliva samples, immediate cooling or addition of preservatives is often required to prevent the breakdown of sensitive biomarkers. Snap freezing—immediately freezing specimens in liquid nitrogen—is commonly used for tissue samples and other biological specimens to preserve proteins and nucleic acids. Stabilization buffers are also used for RNA and protein-based biomarkers to prevent rapid degradation. Moreover, advancements in microfluidics and biopreservation technologies enable the preservation of rare biomarkers at room temperature, making specimen handling and transport easier. Ensuring that each sample is carefully processed and stored according to specific requirements for each biomarker type helps maintain sample integrity, allowing researchers to obtain reliable and reproducible data in biomarker studies.

How Are Technological Advancements Improving Rare Biomarker Collection and Stabilization?

Technological innovations are advancing the collection and stabilization of rare biomarkers, enabling higher sensitivity, accuracy, and preservation. Microfluidic devices allow for the collection and analysis of very small sample volumes, preserving rare biomarkers and minimizing degradation risks. These devices can separate and concentrate biomarkers directly from the sample, eliminating the need for extensive processing and improving efficiency in biomarker isolation. Additionally, stabilizing agents have been formulated to maintain biomarker stability for longer periods, even at room temperature. This reduces the dependency on cold chain logistics and simplifies sample handling and storage, particularly for remote and field-based specimen collection.

Digital PCR (dPCR) and next-generation sequencing (NGS) have also transformed rare biomarker analysis by providing ultra-sensitive detection capabilities, allowing researchers to detect and quantify biomarkers that are present in extremely low concentrations. Furthermore, biosensor-based collection devices are being developed to detect rare biomarkers immediately upon collection, bypassing the need for extensive stabilization and transport processes. Automation and robotic systems are also enhancing specimen collection and handling, reducing the risk of human error and contamination while ensuring that stabilization protocols are followed with precision. These technologies are pivotal in enabling robust biomarker collection and preservation, facilitating the development of more accurate diagnostic tools and personalized treatments.

What Is Driving the Growth in the Rare Biomarker Specimen Collection and Stabilization Market?

The growth in the rare biomarker specimen collection and stabilization market is driven by the increasing demand for precision medicine, advancements in diagnostic technologies, and the rise in complex diseases requiring early detection. As the healthcare industry shifts toward individualized treatment, the need for reliable biomarkers to guide targeted therapies has surged, especially for diseases like cancer and neurological disorders. Researchers and clinicians rely on accurate and stable biomarker data to make informed decisions, and investments in high-quality specimen collection and stabilization tools are essential to meet this demand.

In addition, regulatory requirements and standards for biomarker-based diagnostics are becoming more stringent, especially as companion diagnostics and biomarker-driven therapies gain traction. The need for standardized collection and stabilization protocols is prompting healthcare providers, research institutions, and diagnostic companies to adopt advanced solutions that ensure data accuracy and reproducibility. Growing investment in research and development to identify new biomarkers has also fueled demand for technologies that support rare biomarker preservation. With these factors collectively driving growth, the market for rare biomarker specimen collection and stabilization is poised to expand, paving the way for breakthroughs in diagnostic precision and personalized medicine.

SCOPE OF STUDY:

The report analyzes the Rare Biomarkers Specimen Collection and Stabilization market in terms of US$ Million by the following End-Use; Product Type, and Geographic Regions/Countries:

Segments:

Product Type (Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles, Circulating Cell Free RNA (ccfRNA) / miRNA); End-Use (Research, Diagnostics)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 32 Featured) -

• Advanced Cell Diagnostics, Inc.
• Agena Bioscience
• ANGLE plc
• ApoCell, Inc.
• AS One InternationalNTERNATIONAL
• BioChain Institute, Inc.
• Biolidics Limited
• Biomatrica
• Bio-Techne Corporation
• BioVision, Inc.
• Caltag Medsystems Limited
• Cytomark Ltd.
• DNA Genotek, Inc.
• Epic Sciences
• EpiGentek Group Inc.
• F. Hoffmann-La Roche Ltd
• Fluxion Biosciences, Inc.
• Geno Technology Inc.
• Genomax Technologies Pte Ltd.
• GILUPI GmbH
• LifeSpan BioSciences, Inc.
• MagBio Genomics Inc.
• Menarini Silicon Biosystems
• MyBioSource.com
• Norgen Biotek Corp.
• Novus Biologicals, LLC
• OraSure Technologies Inc.
• Precision for Medicine, Inc.
• Promega Corporation
• QIAGEN
• Rarecells Diagnostics SAS
• RareCyte, Inc.
• siemens Healthineers
• SiO2 Materials Science
• STEMCELL Technologies Inc.
• Streck, Inc.
• Thermo Fisher Scientific, Inc.
• Vortex Biosciences
• VyCAP B.V.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Rare Biomarkers Specimen Collection and Stabilization - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increasing Demand for Precision Medicine Drives Growth in Rare Biomarkers Specimen Collection and Stabilization
  • Rising Prevalence of Chronic and Complex Diseases Spurs Demand for Rare Biomarkers in Early Diagnosis
  • Advancements in Genomics and Proteomics Expand Applications of Rare Biomarker Specimen Collection
  • Growing Focus on Personalized Therapy Boosts Demand for Reliable Collection and Stabilization of Rare Biomarkers
  • Technological Innovations in Sample Preservation Techniques Enhance Quality and Viability of Rare Biomarker Specimens
  • Increasing Adoption of Liquid Biopsy Fuels Market for Non-Invasive Rare Biomarker Collection and Stabilization
  • Expansion of Biobanking and Long-Term Specimen Storage Drives Demand for Stable Rare Biomarker Samples
  • Rising Interest in Multi-Omics Research Spurs Demand for Rare Biomarker Collection in Proteomics and Metabolomics
  • Growing Applications of Rare Biomarkers in Cancer Diagnostics Drive Need for High-Integrity Collection Solutions
  • Collaboration Between Biotech Firms and Healthcare Institutions Fosters Innovation in Rare Biomarker Collection
  • Increasing Awareness of Biomarker Variability and Stability Enhances Demand for Reliable Collection Protocols
  • Expansion of Telemedicine and Remote Diagnostics Creates Opportunities for At-Home Specimen Collection Kits
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 2: World 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
  • TABLE 3: World Recent Past, Current & Future Analysis for Circulating Cell Free DNA (ccfDNA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 4: World 7-Year Perspective for Circulating Cell Free DNA (ccfDNA) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Circulating Tumor Cells (CTCs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World 7-Year Perspective for Circulating Tumor Cells (CTCs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Exosomes / Extracellular Vesicles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 8: World 7-Year Perspective for Exosomes / Extracellular Vesicles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 9: World Recent Past, Current & Future Analysis for Circulating Cell Free RNA (ccfRNA) / miRNA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 10: World 7-Year Perspective for Circulating Cell Free RNA (ccfRNA) / miRNA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 12: World 7-Year Perspective for Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 13: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 14: World 7-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 15: World Rare Biomarkers Specimen Collection and Stabilization Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Rare Biomarkers Specimen Collection and Stabilization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 16: USA Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 17: USA 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2024 & 2030
  • TABLE 18: USA Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 19: USA 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2024 & 2030
• CANADA
  • TABLE 20: Canada Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 21: Canada 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2024 & 2030
  • TABLE 22: Canada Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 23: Canada 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2024 & 2030
• JAPAN
  • Rare Biomarkers Specimen Collection and Stabilization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 24: Japan Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 25: Japan 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2024 & 2030
  • TABLE 26: Japan Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 27: Japan 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2024 & 2030
• CHINA
  • Rare Biomarkers Specimen Collection and Stabilization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 28: China Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 29: China 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2024 & 2030
  • TABLE 30: China Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 31: China 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2024 & 2030
• EUROPE
  • Rare Biomarkers Specimen Collection and Stabilization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 32: Europe Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 33: Europe 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
  • TABLE 34: Europe Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 35: Europe 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2024 & 2030
  • TABLE 36: Europe Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 37: Europe 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2024 & 2030
• FRANCE
  • Rare Biomarkers Specimen Collection and Stabilization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 38: France Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: France 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2024 & 2030
  • TABLE 40: France Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 41: France 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2024 & 2030
• GERMANY
  • Rare Biomarkers Specimen Collection and Stabilization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 42: Germany Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 43: Germany 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2024 & 2030
  • TABLE 44: Germany Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Germany 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2024 & 2030
• ITALY
  • TABLE 46: Italy Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 47: Italy 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2024 & 2030
  • TABLE 48: Italy Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 49: Italy 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2024 & 2030
• UNITED KINGDOM
  • Rare Biomarkers Specimen Collection and Stabilization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 50: UK Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: UK 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2024 & 2030
  • TABLE 52: UK Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 53: UK 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2024 & 2030
• REST OF EUROPE
  • TABLE 54: Rest of Europe Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 55: Rest of Europe 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2024 & 2030
  • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Rest of Europe 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2024 & 2030
• ASIA-PACIFIC
  • Rare Biomarkers Specimen Collection and Stabilization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 58: Asia-Pacific Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 59: Asia-Pacific 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2024 & 2030
  • TABLE 60: Asia-Pacific Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 61: Asia-Pacific 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2024 & 2030
• REST OF WORLD
  • TABLE 62: Rest of World Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 63: Rest of World 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2024 & 2030
  • TABLE 64: Rest of World Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 65: Rest of World 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2024 & 2030

IV. COMPETITION